Hot off the heels of the company’s milestone approval for the unique checkpoint inhibitor Opdualag, Bristol Myers Squibb forged an oncology drug discovery and development deal valued at more than $1 billion with Volastra Therapeutics.

Bristol Myers Squibb Co., in a lawsuit made public on March 17, said AstraZeneca’s cancer treatment Imfinzi violates patents related to the company’s blockbuster cancer drug Opdivo.

Bristol Myers Squibb’s Opdualag – a new, first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as a single intravenous infusion – was approved by the U.S. Food and Drug Administration for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.

Bristol Myers Squibb and Nektar Therapeutics released disappointing news about their joint Phase III PIVOT IO-001 study evaluating a dual therapy of the immunotherapy drug bempegaldesleukin in combination with Opdivo (nivolumab) compared with Opdivo alone to treat unresectable or metastatic melanoma.

Bristol Myers Squibb’s blockbuster cancer drug Revlimid finally has a competitor as Teva Pharmaceuticals announced the launch of a generic version of Revlimid, which could significantly cut into the global biopharmaceutical company’s earnings.

The U.S. Food and Drug Administration approved the expanded use of Bristol Myers Squibb’s cancer drug Opdivo along with chemotherapy as treatment that patients with an aggressive form of lung cancer receive before surgery.

Biohaven Pharmaceutical Holding Company Ltd. entered into a worldwide license agreement with Bristol Myers Squibb Co. for the development and commercialization rights to the novel, Phase 3-ready anti-myostatin adnectin taldefgrobep alfa for spinal muscular atrophy (SMA)

Two-year follow-up data were reported from the Phase III CheckMate -9ER trial of Bristol Myers Squibb’s checkpoint inhibitor Opdivo (nivolumab) and Exelixis’ Cabometyx (cabozantinib) in the first-line treatment of advanced renal cell carcinoma.

Roivant Sciences launched the new subsidiary Hemavant, which hit the ground running with a licensing agreement from Eisai for RVT-2001, a potential first-in-class small molecule SF3B1 modulator.

Prellis Biologics entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb utilizing the Bay Area biotechnology company’s first-in-class externalized human immune system (EXIS) based on human lymph node organoids (LNO).